| name | icsm-consider-tt-normal-psa-no-pca |
| description | Large RCTs show no increased prostate cancer risk with testosterone therapy in men without known prostate cancer and normal PSA, supporting its consideration in this population. This skill is triggered when a clinician evaluates a hypogonadal man with normal PSA and no prior cancer diagnosis and questions whether testosterone therapy is safe to initiate. |
Consider testosterone therapy in men without known prostate cancer and normal PSA
STEP 1 — Gather Information
Collect symptoms of hypogonadism, confirm low total testosterone (<12 nmol/L or <350 ng/dL) on two morning fasting samples, obtain PSA (age‑appropriate normal, e.g., <4 ng/mL), perform DRE to exclude nodules or induration, and verify no history of prostate cancer.
STEP 2 — Rule In / Rule Out
If PSA is within normal limits, DRE is benign, and there is no personal history of prostate cancer, proceed to consider testosterone therapy; otherwise, defer testosterone therapy and refer for urology evaluation before initiation.
STEP 3 — Classify or Stratify
Classify the patient as having low prostate cancer risk based on normal PSA, benign DRE, and absence of known cancer, making testosterone therapy reasonable from an oncologic safety standpoint.
STEP 4 — Decide
Initiate testosterone therapy after shared decision‑making, targeting a mid‑normal testosterone range (approximately 350–750 ng/dL), and schedule baseline and follow‑up monitoring per guideline (symptoms, adverse events, testosterone, hematocrit, PSA, DRE at 3, 6, 6–12 months).
Clinical Guardrails / Mimics / Pitfalls
Do not start testosterone therapy if PSA is elevated or DRE is suspicious without urologic clearance; avoid in men with hematocrit >54% or untreated severe lower urinary tract symptoms; do not ignore the need for baseline and ongoing prostate cancer screening per evidence‑based guidelines; do not use testosterone therapy as monotherapy for erectile dysfunction without confirmed hypogonadism.
Concrete Clinical Example
A 55‑year‑old man presents with fatigue and low libido; two morning total testosterone measurements are 9 nmol/L, PSA is 1.2 ng/mL, DRE is smooth and non‑nodular, and he has no history of prostate cancer. After confirming hypogonadism and normal prostate assessment, the clinician discusses risks/benefits, initiates a transdermal testosterone gel, and arranges follow‑up at 3, 6, and 12 months for symptom response, hematocrit, PSA, and DRE.
Source: Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), International Society for Sexual Medicine, 2025, https://doi.org/10.1093/sxmrev/qeaf036
